Loading...
•
Dec 31, 2023
Edwards Lifesciences Q4 2023 Earnings Report
Edwards Lifesciences reported Q4 2023 financial results, with sales growth driven by its broad portfolio of innovative therapies.
Key Takeaways
Edwards Lifesciences reported a strong Q4 2023, with sales up 14% to $1.53 billion and adjusted EPS of $0.64. The company is confident in its 2024 guidance, projecting 8 to 10 percent constant currency sales growth.
Q4 sales grew 14 percent to $1.53 billion; constant currency sales grew 13 percent.
Q4 TAVR sales grew 13 percent; constant currency sales grew 12 percent.
Q4 EPS of $0.61; adjusted EPS of $0.64.
Executed $400 million accelerated share repurchase in Q4; $867 million repurchased in 2023.
Edwards Lifesciences
Edwards Lifesciences
Edwards Lifesciences Revenue by Segment
Edwards Lifesciences Revenue by Geographic Location
Revenue by Segment
TAVR Revenue
CapyFin.comTMTT Revenue
CapyFin.comSurgical Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comJapan Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
Edwards Lifesciences anticipates full year 2024 sales growth of 8 to 10 percent to $6.3 to $6.6 billion and adjusted earnings per share of $2.70 to $2.80. For the first quarter of 2024, the company projects total sales to be between $1.53 and $1.61 billion, and adjusted EPS of $0.62 to $0.66.
Positive Outlook
- Confident in 2024 guidance of 8 to 10 percent constant currency sales growth
- Full year 2024 sales are expected to grow 8 to 10 percent to $6.3 to $6.6 billion.
- Company continues to expect full year 2024 adjusted earnings per share of $2.70 to $2.80.
- For the first quarter of 2024, the company projects total sales to be between $1.53 and $1.61 billion
- Management now expects full year 2024 TMTT sales at the higher end of the previous $280 to $320 million guidance range as a result of the earlier than expected U.S. approval of EVOQUE.
Revenue & Expenses
Visualization of income flow from segment revenue to net income